Q1 FY27: revenue up 42% YoY, PAT up 49%; Rs 149 Cr capex approved
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 20.3 pts more than Nifty Microcap 250 and 20.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aarti Pharmalabs Q1 FY27: Standalone revenue up 42% YoY at Rs 534.59 Cr, PAT up 49% at Rs 71.31 Cr (EPS Rs 7.87). Consolidated revenue up 39% at Rs 535.80 Cr, PAT up 65% at Rs 76.14 Cr. Board approved Rs 149 Cr capex for new Intermediate Block of 405 KL capacity in 1 year, funded via internal accruals and borrowings. Rashesh Gogri becomes MD, Hetal Gogri Gala moves to Executive Director from Oct 1. Q1 FY26 numbers restated for FX derivative loss.
Strong earnings beat with revenue and profit growth well above 20%. Expansion capex and promoter-led leadership signal confidence.